HCPLive Network

Commonly Prescribed HIV Drug May Cause Memory Loss

 
Researchers at Johns Hopkins recently reported that treatment with the antiretroviral drug efavirenz may contribute to cognitive decline in HIV-infected patients. According to a news release from Johns Hopkins Medicine, “Efavirenz is known to be very good at controlling the virus and is one of the few that crosses the blood-brain barrier and can target potential reservoirs of virus in the brain. Doctors have long believed that it might be possible to alleviate cognitive impairment associated with HIV by getting more drugs into the brain, but researchers say more caution is needed because there may be long-term effects of these drugs on the brain.”
 
The neurocognitive decline that affects a large percentage of HIV patients has long been thought to be a function of the disease itself. But this research suggests that some antiretroviral treatments themselves may contribute to the problem.
 
In the release, Norman J. Haughey, PhD, associate professor of neurology at the Johns Hopkins University School of Medicine, said “we need to be very careful about the types of anti-retrovirals we prescribe, and take a closer look at their long-term effects. Drug toxicities could be a major contributing factor to cognitive impairment in patients with HIV.”
 
In study results published in the Journal of Pharmacology and Experimental Therapeutics, Haughey and colleagues examined the effects of efavirenz and the efavirenz metabolites 7-hydroxyefavirenz (7-OH-EFV) and 8-hydroxyefavirenz (8-OH-EFV) on “calcium, dendritic spine morphology, and survival” in primary neurons cultured in the lab.
 
They reported that efavirenz and its metabolites “each induced neuronal damage in a dose-dependent manner,” with 8-OH-EFV proving to be “at least an order of magnitude more toxic than EFV or 7-OH-EFV, inducing considerable damage to dendritic spines.” They also reported that 8-OH-EFV “evoked calcium flux in neurons” and that “concentrations of EFV and 8-OH-EFV in the cerebral spinal fluid of HIV-infected subjects taking EFV were within the range that damaged neurons in culture.” The authors wrote that these findings “demonstrate that the 8-OH metabolite of EFV is a potent neurotoxin and highlight the importance of directly determining the effects of antiretroviral drugs and drug metabolites on neurons and other brain cells.”
 
The good news for HIV-infected patients is that, according to the Hopkins Medicine news release, “a minor modification in the drug’s structure may be able block its toxic effects but not alter its ability to suppress the virus.” One of the study authors also reported that it is possible to modify the drug “to prevent it from metabolizing into 8-hydroxyefavirenz while maintaining its effectiveness as a tool to suppress the HIV virus.”
 
 
 

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The immune system is the new focus of much work on traumatic brain injury (TBI). In a challenge to the paradigm that the blood brain barrier prevents harmful leukocytes from entering the brain, a Texas team tried to neutralize the impact of these cells. Peripheral lymphocytes are activated after TBI. They may then act as potential antigen presenting cells and get into the brain, causing cells there to degenerate.
Black women undergoing in vitro fertilization are only about half as likely as white women to become pregnant, and the racial disparity persists even when donor eggs are used. These findings are being presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
Hospital conversion to for-profit status is associated with improvements in financial margins, but has no effect on process quality metrics or mortality rates, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
More Reading